BWXT Signs Medical Isotope Development Agreement with Bruce Power
(LYNCHBURG, Va. – July 12, 2018) – BWX Technologies, Inc. (NYSE:BWXT) announced today that a subsidiary has signed an agreement with Bruce Power that will enable the two companies to collaborate on the development and supply of medical isotopes.
BWXT Selects Ontario Power Generation to Provide Irradiation Services for New Medical Isotope Manufacturing Technology
BWX Technologies, Inc. is expanding its longstanding relationship with Ontario Power Generation (OPG), whose wholly owned subsidiary Canadian Nuclear Partners (CNP) plans to provide irradiation services to support BWXT’s new medical isotope manufacturing technology for molybdenum-99.
BWXT Announces Breakthrough Medical Isotope Manufacturing Technology
BWX Technologies, Inc. announced today that it has developed an innovative and unique process to manufacture molybdenum-99 (Mo-99) that will enable a stable, North American supply of this critical diagnostic imaging radionuclide.
BWXT Announces Strategic Acquisition of Sotera Health’s Nordion Medical Isotope Business
BWX Technologies, Inc. (NYSE:BWXT) (“BWXT” or the “Company”) announced today that it has signed a definitive agreement to acquire Sotera Health’s Nordion medical isotope business.